Showing results (2071-2080 of 2,109) with videos related to

Sort By:
Pageof 211
Nature|December 21, 2017
Senescence-associated reprogramming promotes cancer stemnessMaja Milanovic, Dorothy N Y Fan, Dimitri Belenki, et al.
Nature Communications|December 8, 2025
High-density three-dimensional integration of dynamic random-access memory using vertical dual-gate IGZO TFTsFuxi Liao, Zhengyong Zhu, Zihan Li, et al.
Angewandte Chemie (International Ed. in English)|October 31, 2022
Amyloid Against Amyloid: Dimeric Amyloid Fragment Ameliorates Cognitive Impairments by Direct Clearance of Oligomers and PlaquesHee Yang Lee, Seungyeop Baek, Minhae Cha, et al.
Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica|December 6, 2022
[Reflections on supervision strategies of new Tibetan drug registration]Dan Liang, Tsring Pemba, Jiang-Yong Yu, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
MAPT Splicing Modulators as a Therapeutic Strategy for TauopathiesM Catarina Silva, Hannah Lindmeier, Paolo Pigini, et al.
Journal of Synchrotron Radiation|May 13, 2025
An injector testbed based on a direct current gun and an interchangeable very high frequency gun for superconducting continuous-wave free-electron lasersXinmeng Li, Jitao Sun, Yong Yu, et al.
Nature Communications|April 2, 2019
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophanDan-Qian Chen, Gang Cao, Hua Chen, et al.
Nature Communications|March 30, 2025
Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor controlDimitri Belenki, Paulina Richter-Pechanska, Zhiting Shao, et al.
Thoracic Cancer|September 19, 2017
Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancerYan Sun, Jin Wan Wang, Yong Yu Liu, et al.
The Lancet. Oncology|November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Pageof 211